Materialise Invests in Replasia to Support Hip Preservation Innovation

Replasia, a medtech startup developing personalized, 3D-printed solutions and anatomical analysis software for hip preservation, received a minority investment from Materialise and from medtech entrepreneur Andy Christensen.

As part of the collaboration with Materialise, Replasia will draw on the company’s experience in personalized medical solutions, digital planning software, and established pathways to market. Replasia’s portfolio complements Materialise’s existing personalized orthopedic solutions, including patient-specific acetabular implants designed to address complex revision challenges.

Replasia’s flagship solution, the 3D Shelf Implant, is placed outside the joint capsule and is designed to preserve future treatment options. Rather than replacing the joint, Replasia’s technology offers a complementary alternative for selected patients with certain types of hip dysplasia, for whom traditional surgical options can be highly invasive and associated with lengthy rehabilitation.

In August 2025, Replasia initiated a first-in-human clinical investigation in the Netherlands. This study evaluates the 3D Shelf Implant as a less invasive alternative to current standard surgical procedures for adult hip dysplasia and represents significant progress toward broader clinical adoption.

Replasia’s HipStudio is a commercially available, comprehensive service that provides surgeons with accurate measurements to support effective planning for hip preservation treatment.

Replasia noted, “With Materialise’s deep expertise in medical 3D technology and Andy’s outstanding track record and experience in development and commercialization of personalized medical devices, we gain two exceptional partners who will support us in accelerating our product development and market introductions, both in Europe and the USA.”

Sources: Materialise; LinkedIn